In a mouse model of irinotecan-induced nonalcoholic steatohepatitis, SM (1.5 mg/kg) was demonstrated to mitigate increased IL-1β and IL-6 levels and prevented NF-κB overexpression in the liver [227]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatohepatitis.